欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

CDK

CDK

货号 产品名 CAS号 信息
CSN17914 WHI-P180 HCl 153437-55-9 WHI-P180 HCl is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 μM, respectively.
CSN20480 THZ531 1702809-17-3 THZ531 is a covalent CDK12 and CDK13 inhibitor with IC50s of 158 nM and 69 nM.
CSN17944 THZ2 1604810-84-5 THZ2 is a potent and selective CDK7 inhibitor with in vitro IC50 of 13.9 nM.
CSN17959 THZ1-R 1621523-07-6 THZ1-R is a non-cysteine reactive analog, which displays diminished activity for CDK7and reduces anti proliferative potency.
CSN18930 THZ1 Hydrochloride 2070018-35-6 THZ1 HCl is a selective and potent covalent CDK7 inhibitor with IC50 of 3.2 nM.
CSN19264 N-(3-((5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide dihydrochloride 2095433-94-4 THZ1 2HCl is a Cdk7 inhibitor (IC50s = 3.2-15.6 nM in vitro) that selectively targets a remote cysteine residue located outside of the classic kinase domain. THZ1 2HCl also targets Cdk12 kinase activity although at a higher concentration (IC50 = 250 nM).
CSN22287 THAL-SNS-032 2139287-33-3 THAL-SNS-032 is a selective PROTAC, consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN), targeting on CDK9.
CSN20233 TG693 885272-55-9 TG693, an orally available inhibitor of CLK1, promotes the skipping of the endogenous mutated exon 31 in Duchenne muscular dystrophy (DMD) patient-derived cells and increased the production of the functional exon 31-skipped dystrophin protein.
CSN23736 (8E)-6-Methyl-21,22-dihydro-12-oxa-3,6-diaza-2(6,2)-pyrimidina-1,4(1,3)-dibenzenacyclododecaphan-8-ene 1204918-72-8 TG02 (Double bond E) is the Double key form of TG02. TG02 is a small molecule potent CDK2/JAK2/FLT3 inhibitor with IC50s of 13/73/56 nM respectively.
CSN22563 (E/Z)-TG003 300801-52-9 TG003 is a potent, reversible ATP-competitive inhibitor of Cdc-2 like kinase (Clk) with IC50s of 20 nM and 15 nM for Clk1/Sty and Clk4.
CSN20451 3-((1H-Imidazol-5-yl)methylene)-5-methoxyindolin-2-one 666837-93-0 SU9516 (mixture) is a 3-substituted indolinone compound and a competitive inhibitor of CDC2 CDK2 and CDK4 that displaying anti-proliferative and proapoptotic properties in tumor cells. It is the mixture form of SU9516.
CSN23674 SEL120-34A HCl 1609452-30-3 SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
CSN18607 (E/Z)-Zotiraciclib 937270-47-8 SB-1317 is a small molecule potent CDK2/JAK2/FLT3 inhibitor with IC50s of 13/73/56 nM respectively.
CSN19761 Roniciclib 1223498-69-8 Roniciclib is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity, selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation.
CSN18432 RGB-286638 784210-87-3 RGB-286638 is a CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively and less potent against cyclin H-CDK7 and cyclin D3-CDK6.
CSN18433 RGB-286638 free base 784210-88-4 RGB-286638 free base is a CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively and less potent against cyclin H-CDK7 and cyclin D3-CDK6.
CSN22310 CDK9 PROTAC compound 3 2118356-96-8 PROTAC CDK9 Degrader-1 is a CRBN-recruiting PROTAC selectively targeting on CDK9, consist of a CDK9 ligand (aminopyrazole analog) linked to a CRBN E3 ligand thalidomide.
CSN18614 2-(Pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one hydrochloride 942425-68-5 PHA-767491 HCl is a potent and ATP-competitive cyclin-dependent kinase (cdk) inhibitor with IC50 values of 10/34 nM for Cdc7/Cdk9.
CSN18553 NVP-LCQ195 902156-99-4 NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
CSN18926 NU6300 2070015-09-5 NU6300 is the first covalent ATP-competitive CDK2 inhibitor.
CSN19184 NU6027 220036-08-8 NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.
CSN18851 NSC23005 Sodium 1796596-46-7 NSC 23005 Sodium is an effective p18 inhibitor with ED50 of 5.21 nM in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.
CSN19672 MSC2530818 1883423-59-3 MSC2530818 is a Potent, Selective, and Orally Bioavailable CDK8 inhibitor with CDK8 IC50 = 2.6 nM.
CSN18809 LY3177833 1627696-51-8 LY3177833 is an CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively.
CSN17957 LY2857785 1619903-54-6 LY2857785 is a potent and selective CDK9 inhibitor and significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.
CSN20517 LDC4297 1453834-21-3 LDC4297 is a potent CDK7 selective inhibitor with IC50 of 0.13 ± 0.06 nM.
CSN18916 AUZ 454 853299-07-7 K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2 (WT), CDK2 (C118L), CDK2 (A144C), and CDK2 (C118L/A144C), respectlvely.
CSN22284 JH-XI-10-02 2209085-22-1 JH-XI-10-02 is a PROTAC selectively targeting on CDK8 with IC50 value of 159nM, and is consist of a warhead target on CDK8 (a Cortistatin A derivate) linked to CRBN ligand Pomalidomide.
CSN19698 Lerociclib 1628256-23-4 G1T38 is a potent, selective, and orally bioavailable CDK4/6 inhibitor with unique pharmacokinetic and pharmacodynamic properties, which result in high efficacy against CDK4/6 dependent tumors while minimizing the undesirable on-target bone marrow activity.
CSN21361 FN-1501 1429515-59-2 FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively; has anticancer activity.
CSN18431 Dinaciclib 779353-01-4 Dinaciclib is a potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively.
CSN21181 Samuraciclib HCl 1805789-54-1 CT7001 HCl is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively.
CSN22379 CDK12-IN-3 2220184-50-7 CMPD 7 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay.
CSN20276 CLK-IN-T3 2109805-56-1 Clk inhibitor T3 is a highly selective, stable CLK inhibitor with high specificity to CLK1-3 protein isoforms.
CSN20232 Clk Inhibitor C21b 2101206-26-0 Clk inhibitor C21b, a potent inhibitor of Clk1 and -4 (IC50 = 7 and 2.3 nM, respectively), exhibits an unprecedented selectivity over Dyrk1A. It triggered the depletion of EGFR, HDAC1, and p70S6 kinase from the cancer cells, with potencies in line with the measured GI50 values.
CSN17828 Asnuciclib 1421693-22-2 CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM and shows selective toxicity to CLL cells (LD50=80 nM) versus normal B cell and normal CD34+ cell (LD50> 20 μM).
CSN22366 CDK8/19-IN-1 1818427-07-4 CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively.
CSN22368 CDK8-IN-4 1613638-82-6 CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM.
CSN22367 CDK8-IN-3 1884500-15-5 CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7.
CSN19756 Cdc7 inhibitor 7c 1330781-04-8 CDC7 inhibitor C10C is a high selective CDC7 inhibitor.
CSN18782 CCT-251921 1607837-31-9 CCT251921 exhibits excellent pharmacokinetic profile and high potency in vitro and in vivo effects c-Myc downregulation and tumor growth inhibition in xenograft studies.
CSN23778 CC-671 1618658-88-0 CC-671 is a selective inhibitor of TTK (Mps1) and CLK2 with IC50s of 5 nM and 3 nM, respectively.
CSN20540 BRD6989 642008-81-9 BRD6989 selectively upregulates IL-10 through inhibiting CDK8 activity.
CSN24735 AZD4573 2057509-72-3 AZD4573 is a potent and selective CDK9 inhibitor with with nanomolar.
CSN21194 Atuveciclib Racemate 1414943-88-6 Atuveciclib Racemate is the racemate form of Atuveciclib.
CSN17844 AT7519 TFA 1431697-85-6 AT 7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM and less potent to CDK3 and little active to CDK7.
CSN21360 AMG 925 HCl 1401034-19-2 AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively.
CSN22673 Alsterpaullone 237430-03-4 Alsterpaullone is a potent CDK1 and 2 inhibitor with IC50s of 0.035 and 0.08 μM, respectively. It also inhibits GSK-3β and Lck with IC50s of 0.11 and 0.47 μM, respectively.
CSN22626 (R)-CR8 294646-77-8 (R)-CR8 is a cyclin dependent kinase (cdk) inhibitor with IC50 of 0.036 - 0.07 and 0.09 - 0.8 μM for cdk2 and cdk1,respectively.
CSN21345 Enitociclib 1610358-56-9 (+)-BAY-1251152 is a CDK9 inhibitor, Phase 1 of Neoplasms.
<< PREV 1 2 3 4 5 NEXT >>
联系
我们